Sunshine Biopharma Revenue vs. EBITDA

SBFM Stock  USD 3.04  0.60  24.59%   
Based on the key profitability measurements obtained from Sunshine Biopharma's financial statements, Sunshine Biopharma may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Sunshine Biopharma's ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2015-06-30
Previous Quarter
9.3 M
Current Value
8.4 M
Quarterly Volatility
M
 
Yuan Drop
 
Covid
As of the 27th of November 2024, Price To Sales Ratio is likely to drop to 0.26. In addition to that, Days Sales Outstanding is likely to drop to 36.73. At this time, Sunshine Biopharma's Accumulated Other Comprehensive Income is very stable compared to the past year. As of the 27th of November 2024, Income Tax Expense is likely to grow to about 414.9 K, while Income Before Tax is likely to drop (4.3 M).
For Sunshine Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sunshine Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sunshine Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sunshine Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sunshine Biopharma over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(127.90)
Revenue Per Share
197.42
Quarterly Revenue Growth
0.416
Return On Assets
(0.11)
Return On Equity
(0.18)
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Sunshine Biopharma EBITDA vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Sunshine Biopharma's current stock value. Our valuation model uses many indicators to compare Sunshine Biopharma value to that of its competitors to determine the firm's financial worth.
Sunshine Biopharma is rated second in revenue category among its peers. It is currently regarded as top stock in ebitda category among its peers . At this time, Sunshine Biopharma's Total Revenue is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Sunshine Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Sunshine Revenue vs. Competition

Sunshine Biopharma is rated second in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 167.06 Million. Sunshine Biopharma retains roughly 24.09 Million in revenue claiming about 14% of equities under Health Care industry.

Sunshine EBITDA vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Sunshine Biopharma

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
24.09 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Sunshine Biopharma

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(3.82 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Sunshine EBITDA Comparison

Sunshine Biopharma is currently under evaluation in ebitda category among its peers.

Sunshine Biopharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Sunshine Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sunshine Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Sunshine Biopharma's change in net profit over the period of time. It can combine multiple indicators of Sunshine Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income696.1 K730.9 K
Operating Income-4.8 M-4.5 M
Income Before Tax-4.1 M-4.3 M
Net Loss-4.5 M-4.7 M
Income Tax Expense395.2 K414.9 K
Total Other Income Expense Net674.4 K708.1 K
Net Loss-26.8 M-25.4 M
Net Loss-24.1 M-22.9 M
Net Interest Income602.3 K632.4 K
Interest Income736 K460 K
Change To Netincome21.1 M22.1 M
Net Loss(370.41)(388.93)
Income Quality 1.95  2.04 
Net Income Per E B T 1.10  0.77 

Sunshine Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Sunshine Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sunshine Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sunshine Biopharma's important profitability drivers and their relationship over time.

Use Sunshine Biopharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sunshine Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sunshine Biopharma will appreciate offsetting losses from the drop in the long position's value.

Sunshine Biopharma Pair Trading

Sunshine Biopharma Pair Trading Analysis

The ability to find closely correlated positions to Sunshine Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sunshine Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sunshine Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sunshine Biopharma to buy it.
The correlation of Sunshine Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sunshine Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sunshine Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sunshine Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Sunshine Biopharma position

In addition to having Sunshine Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Exotic Funds Thematic Idea Now

Exotic Funds
Exotic Funds Theme
Funds or Etfs with high minimum investment requirement that manage portfolios of alternative investments such as hedge funds, options, futures, real estate or commodities. The Exotic Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Exotic Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Sunshine Biopharma is a strong investment it is important to analyze Sunshine Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sunshine Biopharma's future performance. For an informed investment choice regarding Sunshine Stock, refer to the following important reports:
Check out World Market Map.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
To fully project Sunshine Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sunshine Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sunshine Biopharma's income statement, its balance sheet, and the statement of cash flows.
Potential Sunshine Biopharma investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Sunshine Biopharma investors may work on each financial statement separately, they are all related. The changes in Sunshine Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sunshine Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.